Provisional 2024 EPHMRA ATC Developments
The following new class structures were voted on by EPHMRA/Intellus in May/June 2023 and agreed in principle. These structures will now be used in the next part of the development process which is the detailed refinement of the rules.
Please note that these new class structures are provisional at this time. The 2024 codes, descriptions and Guideline text will be finalised and published by the Committee at the end of 2023. The new structures then come into effect from the beginning of 2024.
Classes affected are:
Drugs for constipation
New fourth level class in A6A (Drugs for constipation) for peripheral opioid receptor antagonist laxatives (currently in A6A9).
JAK inhibitors – cancer-specific
New fourth level class within L1H (Protein kinase inhibitor antineoplastics) for products containing JAK inhibitors that are mainly for cancer. Currently, these products are classified in L1H9 (Protein kinase inhibitor antineoplastics, other).
JAK inhibitors – immune disorders
New third level class within L4 (Immunosuppressants) for products containing JAK inhibitors that are used for a variety of immune disorders. Currently, these products are classified in L4X (Other immunosuppressants).